

REMARKS

Reconsideration is urged in light of the amendments above and comments below:

I. The Rejection of Claim 89 under 35 U.S.C. 112

Claim 89 is cancelled. The remaining rejection is moot.

II: Conclusion

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Should any additional fees be due, the USPTO is authorized to charge the deposit account of Novozymes North America Inc, *i.e.*, Deposit Account 50-1701.

Respectfully submitted,

Date: October 21, 2010

/Michael W. Krenicky Reg.# 45411/
Michael W. Krenicky Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097